Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,497.09 79.56 0.55%
TOPIX 1,169.88 3.29 0.28%
HANG SENG 22,760.24 64.23 0.28%

Aduro Announces Acquisition of GVAX Assets From BioSante



  Aduro Announces Acquisition of GVAX Assets From BioSante

Business Wire

BERKELEY, Calif. -- February 4, 2013

Aduro BioTech, Inc. announces the acquisition of all GVAX assets from BioSante
Pharmaceuticals, Inc. (NASDAQ: BPAX), including intellectual property and cell
lines. This acquisition substantially expands Aduro’s immunotherapy portfolio
and strengthens its competitive position in the field.

Aduro previously licensed two GVAX vaccines, GVAX Pancreas and GVAX Prostate,
for use in combination with its Listeria-based vaccines. This new acquisition
covers all uses and includes additional vaccines for multiple myeloma and
breast and colon cancer and assumes rights to the existing license agreement
for GVAX Melanoma. Under its purchase agreement with BioSante, Aduro paid $1
million upfront and has committed to additional milestone and royalty payments
after commercialization of GVAX product(s).

GVAX vaccines are based on human cancer cell lines that are genetically
modified to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF),
an immune-stimulatory cytokine. “We continue to see promise with GVAX,” said
Stephen Isaacs, chairman and chief executive officer of Aduro. “We believe
that the broad antigen expression and the secretion of GM-CSF make GVAX an
ideal component of combination immunotherapy. We are currently evaluating the
sequential administration of GVAX Pancreas and the Listeria-based CRS-207 in a
randomized, controlled Phase 2 trial in patients with metastatic pancreatic
cancer and the data monitoring committee will review the interim data this
quarter.”

GVAX is one of three Aduro technology platforms, and all three are
interconnected. The live, attenuated Listeria platform has been evaluated in
five clinical trials, including in the ongoing Phase 2 trial in combination
with GVAX Pancreas. In addition, the company has a new platform based on
cyclic dinucleotides (CDNs), which are small molecules secreted by Listeria
and other intracellular pathogens that signal through the STING receptor and
induce strong immune responses. Aduro is combining CDNs with GVAX into a new
vaccine named STINGVAX and has demonstrated superior efficacy over GVAX alone
in animal models.

“Combinations are the future of immunotherapy, especially for cancer ” said
Dr. Thomas W. Dubensky, Jr., chief scientific officer at Aduro. “In addition
to our efforts, other researchers have shown in early-phase pancreatic and
prostate cancer clinical trials that the combination of GVAX with the approved
immune checkpoint inhibitor ipilimumab improves patient outcomes. With the
acquisition of GVAX, we have a unique opportunity to advance an entire
portfolio of combination treatments.”

About Aduro BioTech, Inc.

Aduro BioTech, Inc. is a clinical-stage immunotherapy company located in
Berkeley, California. The company is currently conducting a randomized,
controlled Phase 2 clinical trial in patients with metastatic pancreatic
cancer and a Phase 1B trial in patients with malignant pleural mesothelioma.
The company is also evaluating the synergistic combination of CDNs and GVAX in
preclinical tumor models. Moreover, the company’s pipeline also includes
preclinical programs in glioblastoma, prostate cancer, melanoma, malaria, HBV
and tularemia.

Contact:

Aduro BioTech, Inc.
Steven Bodovitz, Ph.D., +415-336-2700
sbodovitz@adurobiotech.com.
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement